Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01668823 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy in Treating Patients With Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01668823: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT01668823 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01668823, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.
Primary Outcome
Defined as the dose at which =\< 1 out of 6 patients experiences dose-limiting toxicity.
Interventions
- DRUG HPPH
- DRUG photodynamic therapy
- PROCEDURE therapeutic bronchoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT01668823 record still lists
NCT01668823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which HPPH is the first listed.
NCT01668823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01668823 about?
NCT01668823 is a clinical study titled "Photodynamic Therapy in Treating Patients With Lung Cancer". This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.
What is the current status of trial NCT01668823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2004-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01668823?
The interventions under investigation include: HPPH (DRUG), photodynamic therapy (DRUG), therapeutic bronchoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT01668823?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01668823's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia